Results 41 to 50 of about 52,129 (204)

Time-Restricted Feeding Improves Circadian Dysfunction as well as Motor Symptoms in the Q175 Mouse Model of Huntington's Disease. [PDF]

, 2018
Huntington's disease (HD) patients suffer from a progressive neurodegeneration that results in cognitive, psychiatric, cardiovascular, and motor dysfunction.
Colwell, Christopher S, Cutler, Tamara, Howland, David, Loh, Dawn H, Wang, Huei-Bin, Whittaker, Daniel S   +5 more
core   +1 more source

N6-Furfuryladenine is protective in Huntington’s disease models by signaling huntingtin phosphorylation [PDF]

Proceedings of the National Academy of Sciences, 2018
Significance We have discovered a molecule derived from DNA-damage repair that can correct the lack of phosphorylation of mutant huntingtin, the cause of Huntington’s disease (HD). In a mouse model, treatment reverses HD-like disease, and we see the lowering of mutant huntingtin levels to normal.
Laura E. Bowie, Tamara Maiuri, Melanie Alpaugh, Michelle Gabriel, Nicolas Arbez, Danny Galleguillos, Claudia L. K. Hung, Shreya Patel, Jianrun Xia, Nicholas T. Hertz, Christopher A. Ross, David W. Litchfield, Simonetta Sipione, Ray Truant   +13 more
openaire   +5 more sources

Laser Evoked Potentials in Early and Presymptomatic Huntington’s Disease

Behavioural Neurology, 2016
Pain was rarely studied in Huntington’s disease (HD). We presently aimed to extend our previous study on pain pathways functions by laser evoked potentials (LEPs) to a larger cohort of early unmedicated HD patients and a small group of presymptomatic HD (
Marina de Tommaso, Giovanni Franco, Katia Ricci, Anna Montemurno, Vittorio Sciruicchio   +4 more
doaj   +1 more source

Another Perspective on Huntington’s Disease: Disease Burden in Family Members and Pre-Manifest HD When Compared to Genotype-Negative Participants from ENROLL-HD

Brain Sciences, 2021
Background: In addition to the effects on patients suffering from motor-manifest Huntington’s disease (HD), this fatal disease is devasting to people who are at risk, premanifest mutation-carriers, and especially to whole families. There is a huge burden
Jannis Achenbach, Carsten Saft
doaj   +1 more source

Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: Implication for neuroprotective therapies [PDF]

, 2013
Neuroprotective therapies based on brain-derived neurotrophic factor (BDNF) administration have been proposed for Huntington's disease (HD) treatment. However, our group has recently reported reduced levels of TrkB in HD mouse models and HD human brain ...
Alberch, J., Brito, V., Del Toro Ruiz, D., Gines, S., Giralt, A., Puigdellivol, M.   +5 more
core   +1 more source

Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects : a cross-sectional study [PDF]

, 2007
BACKGROUND : Animal data and postmortem studies suggest a role of oxidative stress in the Huntington's disease (HD), but in vivo human studies have been scarce.
Babić, Tomislav, Hećimović, Silva, Klepac, Nataša, Klepac, Ratimir, Relja, Maja, Trkulja, Vladimir   +5 more
core   +1 more source

Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntington’s Disease

Frontiers in Neurology, 2017
The selection of an appropriate segmentation tool is a challenge facing any researcher aiming to measure gray matter (GM) volume. Many tools have been compared, yet there is currently no method that can be recommended above all others; in particular ...
Eileanoir B. Johnson, Sarah Gregory, Hans J. Johnson, Alexandra Durr, Blair R. Leavitt, Raymund A. Roos, Raymund A. Roos, Geraint Rees, Sarah J. Tabrizi, Rachael I. Scahill   +9 more
doaj   +1 more source

Age-related and disease locus-specific mechanisms contribute to early remodelling of chromatin structure in Huntington’s disease mice

Nature Communications, 2021
The dynamics of chromatin and transcriptional changes underlying Huntington’s disease remain poorly understood. Here the authors use a Huntington’s mouse model to profile the striatal chromatin landscape, finding that the Huntington’s mutation ...
Rafael Alcalá-Vida, Jonathan Seguin, Caroline Lotz, Anne M. Molitor, Ibai Irastorza-Azcarate, Ali Awada, Nezih Karasu, Aurélie Bombardier, Brigitte Cosquer, Jose Luis Gomez Skarmeta, Jean-Christophe Cassel, Anne-Laurence Boutillier, Thomas Sexton, Karine Merienne   +13 more
doaj   +1 more source

The Role of Innovation Technology in the Rehabilitation of Patients Affected by Huntington’s Disease: A Scoping Review

Biomedicines, 2023
Huntington’s disease is an autosomal dominant neurodegenerative disease caused by the repetition of cytosine, adenine, and guanine trinucleotides on the short arm of chromosome 4p16.3 within the Huntingtin gene.
Maria Grazia Maggio, Luana Billeri, Davide Cardile, Angelo Quartarone, Rocco Salvatore Calabrò   +4 more
doaj   +1 more source

Neurocardiovascular deficits in the Q175 mouse model of Huntington's disease. [PDF]

, 2017
Cardiovascular dysautonomia as well as the deterioration of circadian rhythms are among the earliest detectable pathophysiological changes in individuals with Huntington's disease (HD). Preclinical research requires mouse models that recapitulate disease
Colwell, Christopher S, Cutler, Tamara S, Ghiani, Cristina A, Jordan, Maria C, Loh, Dawn H, Park, Saemi, Roos, Kenneth P, Yokota, Tomohiro   +7 more
core   +1 more source